The American Joint Committee on Cancer defines stage I non-small cell lung carcinoma
(NSCLC) as consisting of patients with a T1 or T2 primary tumor designation and no …

PURPOSE This phase II trial was designed to evaluate the feasibility, toxicity, response
rates, and survival for neoadjuvant chemotherapy and radiotherapy (RT) followed by …

Twenty to 30% of patients with non-small-cell lung cancer (NSCLC) in stage III are not
resectable primarily with 5-year survival less than 10%. Since the majority of patients die …

PURPOSE AND DESIGN Stage IIIA non-small-cell lung carcinoma (NSCLC) is composed of
regionally advanced yet potentially resectable disease. Many trials have evaluated a variety …

Background Stage IIIB non-small-cell lung cancer (NSCLC) is usually thought to be
unresectable, and is managed with chemotherapy with or without radiotherapy. However …

The treatments for advanced non-small cell lung cancer (NSCLC) should control both local
and microscopic systemic disease, because the 5-year survival of patients with Stage III …

Neoadjuvant therapy has become an accepted treatment for stage IIIa, but not for stage IIIb,
non-small cell lung cancer, which is usually considered incurable and treated nonsurgically …

The multimodalily approach to locally advanced Stage III non-small cell lung cancer is
continuing to evolve. In this trial, 54 patients with surgically staged IIIA disease were treated …

Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …

Introduction: Neoadjuvant therapy in patients with Stage IIIA NSCLC is associated with a 50–
70% resection rate and a 3–5 year survival of 20–32%, but few trials have required …